Search the Newsreel

Smith & Nephew SNATS (NYSE:SNN) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Smith & Nephew SNATS (NYSE:SNN) from a "buy" to a "hold" rating, contributing to a mixed analyst sentiment with an overall "Hold" consensus and a $30.93 price target. The stock opened at $29.84, trading below its 50-day and 200-day moving …

Nephrocare Health Services Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nephros (NEPH) director Arthur Amron granted 2,418 shares, holds 140,874

Nephros Inc. director Arthur H. Amron was granted 2,418 shares of Common Stock on August 12, 2026, as compensation for his board service, increasing his direct holdings to 140,874 shares. He also holds stock options for 7,323 shares fully vested at an exercise price …

Northland Securities Maintains Nephros(NEPH.US) With Hold Rating, Raises Target Price to $4.75

Northland Securities has reiterated its Hold rating on Nephros (NEPH.US) but raised the price target to $4.75. This adjustment indicates a slightly more optimistic outlook on the company's future stock performance by the firm.

August 2026's Promising Penny Stocks

This article highlights three promising penny stocks for August 2026: Nephros (NEPH), Siebert Financial (SIEB), and Douglas Elliman (DOUG). It examines their financial health, recent performance, and strategic initiatives, noting that these companies offer potential for growth despite being smaller or newer entities. The …

Smith & Nephew GAAP EPS of $0.36, revenue of $1.6B

* Smith & Nephew press release [https://seekingalpha.com/filing/309951347] (SNN [https://seekingalpha.com/symbol/SNN]): Q2 GAAP EPS of $0.36. * Revenue of $1.6B (+3.2% Y/Y). * Trading profit for the first half reached $566M, an 8.10% increase year-over-year, expanding the trading profit margin by 60 bps to 18.30%. * …

Smith+Nephew (SNN) lifts H1 2026 profit but cuts revenue growth outlook

Smith+Nephew reported a higher profit for the first half of 2026, with revenue reaching $3,097 million, an increase of 4.6% year-on-year, and trading profit up 8.1% to $566 million. Despite this profit growth, the company revised its full-year underlying revenue growth guidance downwards from …

Smith & Nephew SNATS, Inc. $SNN Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 12.5% in the first quarter, selling 176,622 shares but still retaining over 1.2 million shares valued at approximately $39.4 million. Despite this sale, several other institutional investors increased …

Smith & Nephew (SNN): executive share awards vest, partial sale to cover tax

Smith & Nephew plc reported that performance share awards granted in 2023 to Rohit Kashyap, President of Advanced Wound Management and Global Commercial Operations, vested on August 12, 2026. Of the 23,202 ordinary shares that vested, 9,163 were sold to cover tax liabilities, with …

REG - Smith & Nephew Plc - Director/PDMR Shareholding

Smith & Nephew Plc has announced transactions made by Persons Discharging Managerial Responsibilities (PDMRs) and closely associated persons following the vesting of awards under its Global Share Plan 2020 and Restricted Share Plan 2024. The announcement details the vesting of 2023 Performance Share Awards, …

Cevian increases Smith & Nephew (NYSE: SNN) holding to 14.21% of votes

Cevian Capital II G.P. Limited has increased its aggregate holding in Smith & Nephew plc to 14.214414% of voting rights, corresponding to 119,179,419 shares. This represents a slight increase from its previously notified holding of 14.010786%, with the additional shares held through Cevian Capital …

REG - Smith & Nephew Plc - Holding(s) in Company

Cevian Capital II GP Limited has notified a change in its major holdings in Smith & Nephew Plc, with its total voting rights now at 14.214414%. This increase is primarily due to an increased stake via Cevian Capital II Master Fund L.P., though the …

NEPHROPLUS: Q1 FY 2027 delivered strong revenue and margin growth, with robust international expansion

NEPHROPLUS: Revenue grew 23.7% and adjusted EBITDA 31% year-on-year, with strong international expansion

Smith & Nephew (SNN) Q2 2026 Earnings Call Transcript

Smith & Nephew SNATS, Inc. (SNN) Stock Forecasts

NEPHROS INC Q2 2026: Revenue $6.02M, Net income $1.2M, EPS $0.11— 10-Q Summary

NEPHROS INC reported strong second-quarter 2026 results, with revenue reaching $6.02M and net income soaring to $1.2M, resulting in an EPS of $0.11. The growth was attributed to increased product and service sales, along with improved gross margins due to an IEEPA tariff refund. …

Nephros (NEPH) boosts Q2 2026 profit on revenue growth and tariff refund

Nephros Inc. (NEPH) reported significant financial growth in Q2 2026, with net revenue up 36% to $6.0 million and net income rising to $1.2 million, largely driven by programmatic product growth and a $0.6 million IEEPA tariff refund. Despite this positive performance, the company …

Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Healthcare Innovator with a 12.53% Upside Potential

Smith & Nephew SNATS, Inc. (SNN) is a healthcare innovator with a robust market presence and promising growth potential, offering a 12.53% upside potential based on analyst ratings. The company boasts strong financial health with over $1 billion in free cash flow, 4.60% revenue …

Smith & Nephew SNATS Q2 Earnings Call Highlights

Smith & Nephew Is Under Pressure from External Factors and Portfolio Gaps

Smith & Nephew (SNN) is facing pressure due to external factors and gaps in its product portfolio, despite its history of innovation in orthopedics, sports medicine, and wound care markets. The company has shown strength in introducing innovations like Oxinium technology for hip replacements …

Press Release: Nephros Announces Strong Financial Results for Quarter Ended June 30, 2026

Nephros announced strong financial results for the quarter ended June 30, 2026. The company reported significant revenue growth and improved profitability, driven by strong demand for its innovative filtration products. Management expressed optimism about future growth prospects and their ability to continue delivering value …

Nephros Inc (NEPH) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Nephros Inc (NEPH), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that three analysts rate NEPH as a "Buy" with an average price target of $7.00. The forecast also includes expected …

Smith & Nephew Earnings: Weakness in First Half Could Linger in Second Half

Nephros Inc (NEPH) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge ...

Nephros Inc (NEPH) reported record quarterly revenue of $6 million in Q2 2026, a 36% year-over-year increase, along with a significant surge in net income (over 400%) and Adjusted EBITDA (260%). The growth was attributed to broad-based improvements across product and service revenues, and …

Earnings call transcript: Nephros posts Q2 2026 growth, shares rise premarket

Nephros reported record revenue growth and stronger profitability in Q2 2026, with shares rising premarket despite a slight revenue miss. The company highlighted a 36% increase in revenue to $6.0 million and a significant rise in service-only revenue, driven by existing customers buying more …

Nephros says its service offerings nearly tripled during Q2

Nephros (Nasdaq: NEPH) reported record second-quarter 2026 net revenue of $6.0 million, a 36% increase year-over-year, with core programmatic revenue growing 27%. The company's service offerings nearly tripled compared to the prior year, reflecting increased customer demand for installation, replacement, and water management support. …

Smith & Nephew (LON:SN) Price Target Lowered to GBX 1,290 at JPMorgan Chase & Co.

JPMorgan cuts Smith & Nephew stock rating on market slowdown

JPMorgan downgraded Smith & Nephew PLC to Neutral from Overweight, citing a slowdown in the orthopaedics market and the company's loss of market share in knees and hips. The firm also lowered its price target to GBP12.90 from GBP14.38 and expressed skepticism about the …

JPMorgan cuts Smith & Nephew stock rating on market slowdown By Investing.com

Nephros Q2 2026 Earnings: Revenue Rises 36% as Tariff Refund Lifts Margins

Nephros reported a 36% increase in Q2 2026 net revenue to $6.017 million, with diluted EPS rising to $0.11, significantly boosted by a one-time $0.6 million tariff refund. While the refund inflated profitability, core programmatic revenue still grew 27%, and service-related revenue nearly tripled. …

Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week

Smith+Nephew, the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame, is celebrating mobility, recovery, and football traditions during the 2026 Pro Football Hall of Fame Enshrinement Week in Canton, Ohio. The company will host an interactive booth …

Nephros to File Q2 Results After Close, Host 4:30 ET Call

Nephros (Nasdaq: NEPH) announced it will file its second-quarter 2026 financial results after market close on Thursday, August 06, 2026. The company will host a conference call on the same day at 4:30 p.m. ET. Dial-in details for domestic and international participants, along with …